Back to discover
Disease
Disruptive, Impulse Control, and Conduct Disorders
Late-stage therapeutic developmentEmerging research
1
Publications
24
Clinical trials
2024
Latest publication
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
Management of Impulse Control and Related Disorders in Parkinson's Disease: An Expert Consensus.
Research2024-01-17Movement disorders : official journal of the Movement Disorder Society
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Moderate
Key developments
- 5 clinical trials expected to report results, the earliest in Q3 2027.
Upcoming Milestones
- Q3 2027Cannabidiol-Enhanced Cognitive Behavioral Therapy for Generalized Anxiety Disorder
- Q4 2027Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression
- Q1 2030A Pharmaco-Imaging Trial of Mixed Amphetamine Salts for the Treatment of ADHD in Intellectually-intact Youth With Autism Spectrum Disorder
- Q1 2030Mechanistic Clinical Trial Evaluating the Role of the Metabotropic Glutamate Receptor Subtype 5 (mGluR5) in the Antidepressant Mechanism of Cognitive Behavioral Therapy for Insomnia (CBT-I)
- Q1 2031CELESTE: Comparative Effectiveness Study of behavioraL and Drug-rElated inSomnia Therapies for pEri- and Post-menopausal People
Major developments
Major trial resultsHigh impact
Results posted2026-07-02
Major trial resultsHigh impact
Results posted2026-04-13
Clinical MilestonesView all 11Hide
Results posted
- 2026-07-02CPT-SMART for Treatment of PTSD and Cigarette SmokingResults posted
- 2026-04-13A Phase 4, Multicenter, 2-part Study Composed of a Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator, Dose-optimization Evaluation Followed by a 1-Year Open-label Evaluation to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged-release (SPD503) in Children and Adolescents Aged 6 to 17 Years With Attention-deficit/Hyperactivity DisorderResults posted
- 2025-10-10Pain Response Evaluation of a Combined Intervention to Cope Effectively (PRECICE)Results posted
- 2025-09-10iKanEat: A Randomized-controlled, Multi-center Trial of Megestrol for Chronic Oral Food Refusal in Children 9 Months to 9 Years 0 Months of AgeResults posted
Results expected
- 2026-06-08CELESTE: Comparative Effectiveness Study of behavioraL and Drug-rElated inSomnia Therapies for pEri- and Post-menopausal PeopleResults expected Q1 2031
- 2026-03-09Cannabidiol-Enhanced Cognitive Behavioral Therapy for Generalized Anxiety DisorderResults expected Q3 2027
- 2026-03-06A Pharmaco-Imaging Trial of Mixed Amphetamine Salts for the Treatment of ADHD in Intellectually-intact Youth With Autism Spectrum DisorderResults expected Q1 2030
- 2026-02-17Mechanistic Clinical Trial Evaluating the Role of the Metabotropic Glutamate Receptor Subtype 5 (mGluR5) in the Antidepressant Mechanism of Cognitive Behavioral Therapy for Insomnia (CBT-I)Results expected Q1 2030
- 2025-10-31Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and DepressionResults expected Q4 2027
Recently completed
+3 more in the activity timeline below
Activity timeline11
- 2026-07-02ClinicalCPT-SMART for Treatment of PTSD and Cigarette SmokingResults posted
- 2026-06-08ClinicalCELESTE: Comparative Effectiveness Study of behavioraL and Drug-rElated inSomnia Therapies for pEri- and Post-menopausal PeopleResults expected Q1 2031
- 2026-04-30ClinicalThe Effects of Solriamfetol and CBT-I (Alone and in Combination) on Sleep Continuity, Sleepiness, Fatigue, and Performance in Patients With Insomnia DisorderCompleted
- 2026-04-13ClinicalA Phase 4, Multicenter, 2-part Study Composed of a Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator, Dose-optimization Evaluation Followed by a 1-Year Open-label Evaluation to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged-release (SPD503) in Children and Adolescents Aged 6 to 17 Years With Attention-deficit/Hyperactivity DisorderResults posted
- 2026-03-09ClinicalCannabidiol-Enhanced Cognitive Behavioral Therapy for Generalized Anxiety DisorderResults expected Q3 2027
- 2026-03-06ClinicalA Pharmaco-Imaging Trial of Mixed Amphetamine Salts for the Treatment of ADHD in Intellectually-intact Youth With Autism Spectrum DisorderResults expected Q1 2030
- 2026-02-17ClinicalMechanistic Clinical Trial Evaluating the Role of the Metabotropic Glutamate Receptor Subtype 5 (mGluR5) in the Antidepressant Mechanism of Cognitive Behavioral Therapy for Insomnia (CBT-I)Results expected Q1 2030
- 2025-10-31ClinicalProcesses and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and DepressionResults expected Q4 2027
- 2025-10-10ClinicalPain Response Evaluation of a Combined Intervention to Cope Effectively (PRECICE)Results posted
- 2025-09-10ClinicaliKanEat: A Randomized-controlled, Multi-center Trial of Megestrol for Chronic Oral Food Refusal in Children 9 Months to 9 Years 0 Months of AgeResults posted
Clinical trials
The current development programme across all trial phases.
Clinical programme
24
6
18
6
Late-stage studies
Recruiting
Recently completed
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Most influential
Major themes4
- Deep Brain Stimulation1
- Disruptive, Impulse Control, and Conduct Disorders1
- Mental Disorders1
- Parkinson Disease1
Leading journals1
- Movement disorders : official journal of the Movement Disorder Society1
Leading researchers8
- Amstutz D1
- Cardoso F1
- Corvol JC1
- Debove I1
- Deuschl G1
- Fung VSC1
- Krack P1
- Lang AE1
Affiliations (unnormalised)6
- Center for Networked Biomedical Research in Neurodegenerative Diseases (CIBERNED)1
- Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic1
- Education and Clinical Center (PADRECC and MIRECC)1
- Perelman School of Medicine at the University of Pennsylvania1
- Sorbonne Université1
- The Federal University of Minas Gerais1
Reference
Authoritative identity, definition & identifiers.
Defined in MeSH
Disorders whose essential features are the failure to resist an impulse, drive, or temptation to perform an act that is harmful to the individual or to others. Individuals experience an increased sense of tension prior to the act and pleasure, gratification or release of tension at the time of committing the act.
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.